Ardent Health (NYSE:ARDT) Issues FY 2026 Earnings Guidance

Ardent Health (NYSE:ARDT) updated its FY 2026 earnings guidance on Wednesday. The company provided EPS guidance of 0.900-1.270 for the period, compared to the consensus EPS estimate of 1.400. The company issued revenue guidance of $6.4 billion-$6.7 billion, compared to the consensus revenue estimate of $6.7 billion.

Ardent Health Price Performance

NYSE ARDT traded up $0.18 during trading hours on Wednesday, reaching $9.59. 368,054 shares of the company’s stock were exchanged, compared to its average volume of 401,265. The firm has a fifty day moving average of $8.98 and a 200-day moving average of $11.05. Ardent Health has a one year low of $8.07 and a one year high of $15.48. The stock has a market cap of $1.37 billion, a PE ratio of 6.61, a price-to-earnings-growth ratio of 5.22 and a beta of 0.46. The company has a current ratio of 2.08, a quick ratio of 1.95 and a debt-to-equity ratio of 0.67.

Ardent Health (NYSE:ARDT) last posted its quarterly earnings data on Wednesday, March 4th. The company reported $0.32 EPS for the quarter, missing analysts’ consensus estimates of $0.35 by ($0.03). Ardent Health had a return on equity of 19.02% and a net margin of 3.24%.The business had revenue of $1.61 billion during the quarter, compared to analyst estimates of $1.63 billion. Ardent Health has set its FY 2026 guidance at 0.900-1.270 EPS. On average, equities research analysts predict that Ardent Health will post 1.23 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. KeyCorp cut Ardent Health from an “overweight” rating to a “sector weight” rating in a report on Monday, November 17th. UBS Group reduced their price objective on shares of Ardent Health from $14.50 to $14.00 and set a “buy” rating on the stock in a research note on Thursday, December 18th. JPMorgan Chase & Co. dropped their target price on shares of Ardent Health from $12.00 to $11.00 and set a “neutral” rating for the company in a research report on Tuesday, January 20th. Morgan Stanley reissued an “equal weight” rating and issued a $12.00 price target (down from $22.00) on shares of Ardent Health in a research note on Friday, November 14th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Ardent Health in a research note on Monday, December 29th. Six investment analysts have rated the stock with a Buy rating, four have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $14.58.

More Ardent Health News

Here are the key news stories impacting Ardent Health this week:

• Positive Sentiment: Ardent confirmed it will participate in March investor conferences — a chance for management to engage with investors and address the receivables/accounting issues directly, which could help calm markets if management provides clear updates. Ardent Health to Participate in March Investor Conferences
• Neutral Sentiment: One firm (Faruqi & Faruqi) cited a later April 21, 2026 deadline for lead‑plaintiff applications — a different date than many other notices — which may prolong headline risk and create scheduling/coordination uncertainty for potential plaintiffs. ARDT SHAREHOLDER REMINDER
• Negative Sentiment: Multiple national law firms (Hagens Berman, RGRD, Bronstein Gewirtz, Levi & Korsinsky, Rosen, Kahn Swick & Foti, Bleichmar Fonti & Auld, others) are actively soliciting Ardent investors to join or lead a securities class action tied to disclosures covering July 18, 2024–Nov 12, 2025; that cascade of notices increases litigation risk and ongoing headline pressure. MONDAY DEADLINE: Ardent Health, Inc. Investors…
• Negative Sentiment: Hagens Berman and others point to an alleged ~$97M “accounting shock” tied to Ardent’s use of a rigid “180‑day cliff” to reserve for uncollectible accounts — an approach the complaints say contradicts prior statements about detailed historical collection reviews. That specific allegation is the core catalyst for the prior ~33% stock drop and could lead to financial restatements, reserves, or regulatory scrutiny. ARDT WRITE OFFS: Hagens Berman Investigating Claims…

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of ARDT. Caitong International Asset Management Co. Ltd increased its position in shares of Ardent Health by 1,177.7% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 2,862 shares of the company’s stock worth $25,000 after acquiring an additional 2,638 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Ardent Health in the 3rd quarter worth $61,000. New York State Common Retirement Fund increased its holdings in Ardent Health by 121.4% during the 2nd quarter. New York State Common Retirement Fund now owns 6,200 shares of the company’s stock worth $85,000 after purchasing an additional 3,400 shares in the last quarter. Squarepoint Ops LLC bought a new position in Ardent Health during the 3rd quarter worth about $145,000. Finally, Fox Run Management L.L.C. acquired a new stake in shares of Ardent Health in the 4th quarter valued at about $147,000.

About Ardent Health

Ardent Health, listed on the New York Stock Exchange under the ticker ARDT, is a healthcare delivery company focused on acquiring, developing and managing acute care hospitals and complementary outpatient facilities across the United States. The company’s integrated platform encompasses both inpatient and outpatient services, designed to provide end-to-end care solutions and address the full continuum of patient needs.

Through its network, Ardent Health operates general hospitals, emergency departments, ambulatory surgery centers, urgent care clinics, rehabilitation and post-acute care facilities.